JP MORGAN/CALL/ABBOTT LABORATORIES/155/0.1/17.01.25 Stock

Warrant

DE000JL03GM9

Real-time Bid/Ask 01:08:03 2024-06-04 pm EDT
0.006 EUR / 0.026 EUR +220.00% Intraday chart for JP MORGAN/CALL/ABBOTT LABORATORIES/155/0.1/17.01.25
Current month+25.00%
1 month-54.55%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-06-04 0.005 0.00%
24-06-03 0.005 +25.00%
24-05-31 0.004 0.00%
24-05-30 0.004 0.00%
24-05-29 0.004 -33.33%

Delayed Quote Börse Stuttgart

Last update June 04, 2024 at 03:19 am EDT

More quotes

Static data

Product typePlain-Vanilla-Warrants
Buy / SellCALL
Underlying ABBOTT LABORATORIES
Issuer J.P. Morgan
WKN JL03GM
ISINDE000JL03GM9
Date issued 2023-04-05
Strike 155 $
Maturity 2025-01-17 (227 Days)
Parity 10 : 1
Emission price 0.14
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 0.31
Lowest since issue 0.004
Spread 0.02
Spread %80.00%

Company Profile

Abbott Laboratories specializes in the research, development, manufacturing and marketing of pharmaceutical and medical products. Net sales break down by family of products as follows: - diagnostic systems and instruments (39.1%); - vascular devices (24.7%): endoprosthetic systems, dilation catheters, arterial closures, etc.; - nutrition products (12.1%): pediatric nutrition products, nutritional supplements, and dietetic products; - medicine (8.2%): anesthetics, antiviral products, antibiotics, inhibitors, anti-inflammatories, etc.; - other (15.9%). Net sales are distributed geographically as follows: the United States (38.5%), Germany (5.8%), China (5.6%), India (4.4%), Switzerland (4.1%), Japan (3.8%), Netherlands (2.7%) and others (35.1%).
Sector
-
More about the company

Ratings for Abbott Laboratories

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

Consensus: Abbott Laboratories

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
102.9 USD
Average target price
125.4 USD
Spread / Average Target
+21.88%
Consensus